NYSE - Delayed Quote USD

Abbott Laboratories (ABT)

107.27 -0.26 (-0.24%)
At close: April 29 at 4:00 PM EDT
107.01 -0.26 (-0.24%)
Pre-Market: 7:05 AM EDT
Loading Chart for ABT
DELL
  • Previous Close 107.53
  • Open 107.39
  • Bid 106.44 x 800
  • Ask 107.20 x 800
  • Day's Range 106.60 - 108.19
  • 52 Week Range 89.67 - 121.64
  • Volume 3,305,055
  • Avg. Volume 5,760,720
  • Market Cap (intraday) 186.133B
  • Beta (5Y Monthly) 0.74
  • PE Ratio (TTM) 33.42
  • EPS (TTM) 3.21
  • Earnings Date Jul 18, 2024 - Jul 22, 2024
  • Forward Dividend & Yield 2.20 (2.05%)
  • Ex-Dividend Date Apr 12, 2024
  • 1y Target Est 118.35

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

www.abbott.com

114,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ABT

Performance Overview: ABT

Trailing total returns as of 4/29/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ABT
1.59%
S&P 500
7.26%

1-Year Return

ABT
0.93%
S&P 500
22.71%

3-Year Return

ABT
6.79%
S&P 500
22.30%

5-Year Return

ABT
48.65%
S&P 500
74.03%

Compare To: ABT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ABT

Valuation Measures

Annual
As of 4/29/2024
  • Market Cap

    186.13B

  • Enterprise Value

    194.48B

  • Trailing P/E

    33.42

  • Forward P/E

    23.09

  • PEG Ratio (5yr expected)

    5.85

  • Price/Sales (ttm)

    4.65

  • Price/Book (mrq)

    4.82

  • Enterprise Value/Revenue

    4.82

  • Enterprise Value/EBITDA

    21.54

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.96%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    40.33B

  • Net Income Avi to Common (ttm)

    5.61B

  • Diluted EPS (ttm)

    3.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.28B

  • Total Debt/Equity (mrq)

    40.88%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: ABT

Company Insights: ABT

Research Reports: ABT

People Also Watch